Pre-weighed oral powders for swine are prepared by distributing a dry extract of Carpesii Fructus veterinary-grade API on a spray-dried lactose carrier with colloidal silicon dioxide as a flow modifier. A representative development batch uses 15.0% by weight dry extract, 84.0% spray-dried lactose, 0.5% colloidal silicon dioxide, and 0.5% sodium starch glycolate; the extract is first passed through a 500 µm stainless-steel screen and assayed to adjust the final fill weight on a dried-weight basis. Because the native extract shows harvest-dependent bulk density variation, every incoming lot is re-qualified for loss on drying under USP <731>, and lots exceeding 5.0% residual moisture are rejected before batching. Blending is performed in a 200 L bin blender at 10 rpm for 20 min, followed by sampling at 10 positions according to ISO 6497:2002; the batch is released only when the relative standard deviation for the marker peak is no greater than 5.0%. Powder flow is assessed under Ph. Eur. 2.9.36, and the cohesion index is used to set sachet fill speed. The resulting powder is filled into heat-sealed laminated foil sachets of 100 g net weight, and moisture ingress is controlled to below 0.5% after 24 months at 25 °C and 60% relative humidity. Microbial quality is assessed under Ph. Eur. 5.1.4, and residual solvent levels from extract manufacture are checked against VICH GL18. This presentation is selected where individual animal dosing is preferred over large-volume feed inclusion, and it avoids the feed refusal patterns observed with coarse botanical powders when final mixture particle size exceeds 450 µm.

What Limits Direct Compression Throughput on Rotary Tablet Presses?

Direct compression of Carpesii Fructus dry extract without prior granulation is constrained by its low bulk density, poor compactability, and moisture uptake above 60% relative humidity, which can increase tablet weight variation beyond USP <905> limits. A wet granulation route is therefore used for companion-animal tablets. A representative formulation contains 20.0% dry extract, 44.0% microcrystalline cellulose, 30.0% lactose monohydrate, 3.0% crospovidone, 1.0% polyvinylpyrrolidone K30 as binder, 1.0% talc, and 1.0% magnesium stearate. The extract and fillers are granulated in a high-shear mixer at impeller 300 rpm and chopper 1500 rpm with purified water added to 8.0% by weight; the granulation endpoint is reached when the torque rise reaches 8–10% above the dry-mix baseline. The wet mass is dried in a fluid-bed dryer at inlet 55 °C until loss on drying is no more than 3.0% under USP <731>. The dried granules are milled through a 1.0 mm screen, and the fraction retained on a 1.4 mm sieve is remilled. Magnesium stearate is sieved through a 0.5 mm screen and blended separately for 3 min at 8 rpm to avoid overlubrication. Compression is performed on a 27-station rotary press with 8.0 mm round concave tooling at precompression 6 kN and main compression 14–16 kN. Hardness is held at 70–90 N, friability is below 1.0% under USP <1216>, and disintegration is below 15 min under USP <701> in 0.1 M hydrochloric acid. The tablets are film-coated with a polyvinyl alcohol-based aqueous coating to 3.0% weight gain and packaged in high-density polyethylene bottles with silica gel desiccant.

When Carpesii Fructus Extract Is Processed into Sterile Injectable Solutions

Because injectable presentations require sterility, low endotoxin burden, and removal of insoluble botanical fragments, the extraction lot is pre-treated before dissolution in a non-aqueous vehicle. A representative development formulation contains 5.0% dry extract, 1.5% benzyl alcohol, 0.2% polysorbate 80, and propylene glycol to 100%. The extract is dissolved at 40 °C under nitrogen, prefiltered through a 0.45 µm polypropylene membrane, and sterilized by passage through a 0.22 µm polyvinylidene fluoride membrane rated for low-moisture solvent systems. Filter integrity is confirmed by diffusion-flow analysis before and after filling, and the pressure drop across the sterilizing filter is not permitted to exceed 1.0 bar. Glass vials are depyrogenated at 250 °C for 30 min, and the filling line operates under EU GMP Annex 1-grade conditions with continuous viable and non-viable particle monitoring. Endotoxin is controlled to no more than 0.5 EU/mg of extract by Ph. Eur. 2.6.14, and the absence of sub-visible particulate matter is confirmed by light obscuration under Ph. Eur. 2.9.19. Terminal steam sterilization is avoided because the marker sesquiterpene lactones degrade rapidly at 121 °C; published data for this specific extract configuration are limited, so thermal mapping and forced-degradation studies are required for each new lot. The final container is a 50 mL amber Type I glass vial with bromobutyl rubber closure. This dosage form is reserved for prescriber-supervised administration where oral ingestion is not feasible, and the non-aqueous vehicle imposes a handling incompatibility with polycarbonate syringes during dose withdrawal.

Ruminant Premix Homogeneity and Micro-Ingredient Segregation

For feed-mill incorporation, a carrier-based premix is produced by coating soybean hulls with a dispersed botanical extract and oil binder. A representative formulation uses 10.0% Carpesii Fructus extract, 88.0% soybean hulls of 0.8–1.4 mm particle size, 1.5% soybean oil, and 0.5% precipitated silica. Mixing is conducted in a 500 kg horizontal ribbon mixer at 12 rpm for 15 min; the oil is preheated to 45 °C and sprayed through a two-fluid nozzle to improve extract adhesion. Batch release requires 10 sampling points per ISO 6497:2002, and the marker assay relative standard deviation must be no greater than 10.0% to avoid uneven field exposure. Sampling is performed with a multi-chamber thief to detect vertical segregation; if the top-to-bottom marker deviation exceeds 8.0%, the batch is remixed for an additional 10 min. The finished premix is filled into 25 kg paper valve bags with a polyethylene inner liner and stored below 25 °C and 60% relative humidity. Processing with molasses-based liquid feeds is not recommended because water activity above 0.75 promotes extract caking and microbial growth. This premix is intended for dilution at the feed mill; a representative final feed inclusion range of 0.5–2.0 kg/t is adjusted by assay, and the accuracy of the micro-ingredient dosing system is verified by tracer recovery tests using iron powder according to ISO 6498:2012.

Water-soluble granules for poultry drinking-water systems are produced through fluid-bed top-spray granulation to meet a narrow particle-size window imposed by proportioner pumps. A representative granulation batch uses 20.0% dry extract, 55.0% lactose monohydrate, 12.0% mannitol, 8.0% polyvinylpyrrolidone K30, and 5.0% crospovidone. Granulation is performed in a fluid-bed top-spray unit with inlet air 60 °C, product temperature 40 °C, atomizing pressure 1.5 bar, and spray rate 80 g/min for a 10 kg batch; dried granules are sieved to 0.6–1.4 mm and moisture is controlled below 2.5% under USP <731>. The acceptance test includes complete dispersion through a 0.5 mm screen in tap water at 25 °C within 60 s, with no visible surface oiling. The terminal package is a 100 g high-density polyethylene jar with induction-sealed liner, and each lot is assayed by high-performance liquid chromatography before release. Water medication lines constructed from galvanized steel are not recommended because acidic or chelating constituents in the botanical extract may accelerate metal ion leaching; polypropylene or stainless-steel dosing lines are preferred. In-line dilution systems require a flushing volume of at least 2 L after medication to clear residual extract from the proportioner chamber.

A Colloid Mill Route Preserves Suspension Viscosity for Liquid-Filled Capsules

To maintain fill homogeneity at low viscosity, liquid-filled hard capsules are produced by dispersing the extract in medium-chain triglycerides and reducing particle size through a colloid mill. A representative formulation contains 12.0% dry extract, 70.0% medium-chain triglycerides, 3.0% hydrogenated castor oil, 1.0% lecithin, 2.0% fumed silica, and 0.02% butylated hydroxytoluene as antioxidant. The extract is first micronized in a jet mill to a median particle size below 50 µm, then dispersed in the oil phase using a high-shear mixer at 3000 rpm for 15 min; the suspension is passed twice through a colloid mill with a 50 µm gap and deaerated under vacuum at -0.08 MPa for 30 min. Viscosity is monitored with a rotational viscometer and maintained between 800 mPa·s and 1200 mPa·s at 25 °C to prevent capsule settling during filling. The suspension is filled into size 0 hydroxypropyl methylcellulose capsules on a piston-type filling machine, and the cap-body joint is sealed with a 25% hydroxypropyl methylcellulose solution. Content uniformity follows USP <905>, and the capsules are blister-packed in cold-form foil. This presentation is intended for companion-animal outpatient dosing, and the oil-based fill limits use with polyvinyl chloride blister films due to plasticizer migration. Capsule fill weight is set at 500 mg, and in-process checks are taken every 15 min during filling to maintain fill-weight relative standard deviation below 2.0%.